70 Radiation pneumonitis in lung cancer patients treated with high dose radiotherapy — role of concurrent medications

2005 ◽  
Vol 76 ◽  
pp. S21-S22
Author(s):  
A. Bezjak ◽  
V. Soyfer ◽  
Q.-L. Yi ◽  
A. Sun ◽  
G. Kane ◽  
...  
2019 ◽  
Vol 61 (1) ◽  
pp. 117-122
Author(s):  
Tianle Shen ◽  
Liming Sheng ◽  
Ying Chen ◽  
Lei Cheng ◽  
Xianghui Du

Abstract Silica is an independent risk factor for lung cancer in addition to smoking. Chronic silicosis is one of the most common and serious occupational diseases associated with poor prognosis. However, the role of radiotherapy is unclear in patients with chronic silicosis. We conducted a retrospective study to evaluate efficacy and safety in lung cancer patients with chronic silicosis, especially focusing on the incidence of radiation pneumonitis (RP). Lung cancer patients with chronic silicosis who had been treated with radiotherapy from 2005 to 2018 in our hospital were enrolled in this retrospective study. RP was graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Of the 22 patients, ten (45.5%) developed RP ≥2. Two RP-related deaths (9.1%) occurred within 3 months after radiotherapy. Dosimetric factors V5, V10, V15, V20 and mean lung dose (MLD) were significantly higher in patients who had RP >2 (P < 0.05). The median overall survival times in patients with RP ≤2 and RP>2 were 11.5 months and 7.1 months, respectively. Radiotherapy is associated with excessive and fatal pulmonary toxicity in lung cancer patients with chronic silicosis.


Author(s):  
Paolo Borghetti ◽  
Cristian Toraci ◽  
Jessica Imbrescia ◽  
Giulia Volpi ◽  
Silvia Lucchini ◽  
...  

2017 ◽  
Vol 12 (1) ◽  
pp. S1142-S1143
Author(s):  
Andika Putra ◽  
Keiko Hiyama ◽  
Keiji Tanimoto

Sign in / Sign up

Export Citation Format

Share Document